Measuring the patient-centred effectiveness of PHACO-MIGS using GlauCAT
PHACO-MIGS can significantly improve a range of quality of life outcomes in patients with early stage glaucoma.
Assessing cost-effectiveness of glaucoma treatments with Glau-U
Glau-U utilities decreased as glaucoma severity increased, demonstrating reductions of up to 41% in quality-adjusted life-years compared with glaucoma suspects.